PBM Reform 2026: What Recent Legislation Means for the Industry
Date: March 17, 2026
Time: 12:30PM - 1:30PM (EST)
The pharmacy benefit manager (PBM) landscape underwent significant regulatory transformation, with a wave of developments signaling a new era of transparency and accountability for PBMs and the entities that contracted with them. In early 2026 alone, Congress passed landmark PBM reforms in the Consolidated Appropriations Act of 2026, the Department of Labor (DOL) proposed new rules for group health plans’ relationships with PBMs, the FTC settled enforcement actions, and the Trump administration launched TrumpRx.gov as part of its broader drug pricing initiatives.
Attorneys from our Health Law practice led a practical discussion on what these changes meant for organizations. They broke down the key provisions of the CAA 2026 PBM reforms, explored the DOL’s proposed rule and its implications for plan sponsors and PBMs, examined recent FTC settlements, and assessed how the administration’s drug pricing initiatives might shape the market going forward.
Attendees came away ready to:
- Prioritize compliance efforts based on the CAA 2026 PBM reform provisions and key timelines
- Monitor the DOL’s proposed rule and prepare for its potential impact on PBM–plan sponsor relationships
- Discuss and, if necessary, implement operational changes aligned with the standards set by recent FTC settlements
- Position their organizations for growth amid ongoing regulatory change
Who should have attended: PBMs, health plans, pharmaceutical manufacturers, pharmacies, rebate aggregators, and investors in the health care space.
This webinar helped organizations prioritize, implement, and monitor these new requirements without disrupting current operations and positioned them for future growth in an evolving regulatory environment.
